Skip to main content

Knife River Corp

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

KNF$58.43-0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

16. Income Taxes

Note 16 –Income Taxes

Income tax expense on the Consolidated Statements of Operations for the years ended December 31 was as follows:

202320222021
(In thousands)
Current:
Federal$45,746$27,293$4,270
State18,29613,2306,331
64,04240,52310,601
Deferred:
Income taxes:
Federal2631,71526,793
State(1,869)3636,065
(1,606)2,07832,858
Total income tax expense$62,436$42,601$43,459

Components of deferred tax assets and deferred tax liabilities at December 31 were as follows:

20232022
(In thousands)
Deferred tax assets:
Deferred compensation/compensation related$22,358$15,329
Operating lease liabilities11,46811,804
Asset retirement obligations10,8629,687
Net operating loss/credit carryforward10,81112,039
Accrued pension costs10,55611,070
Capitalized inventory overheads7,3887,260
Other9,4588,412
Total deferred tax assets$82,901$75,601
20232022
(In thousands)
Deferred tax liabilities:
Basis differences on property, plant and equipment$206,507$203,099
Intangible assets12,22010,975
Operating lease right-of-use-assets11,46811,804
Other16,43713,488
Total deferred tax liabilities246,632239,366
Valuation allowance10,81112,039
Net deferred income tax liability$(174,542)$(175,804)

As of December 31, 2023 and 2022, the Company had various state income tax net operating loss carryforwards of $133.6 million and $160.1 million, respectively, and federal and state income tax credit carryforwards, excluding alternative minimum tax credit carryforwards, of $591,000 for both years. The state income tax credit carryforwards are due to expire in 2024. Changes in tax regulations or assumptions regarding current and future taxable income could require additional valuation allowances in the future.

The following table reconciles the change in the net deferred income tax liability from December 31, 2022, to December 31, 2023, to deferred income tax expense:

20232022
(In thousands)
Change in net deferred income tax liability from the preceding table$(1,262)$7,278
Deferred income taxes established due to an acquisition—(1,215)
Deferred taxes associated with other comprehensive loss(344)(3,985)
Deferred income tax expense for the period$(1,606)$2,078

Total income tax expense differs from the amount computed by applying the statutory federal income tax rate to income before taxes. The reasons for this difference were as follows:

Years ended December 31,202320222021
Amount%Amount%Amount%
(Dollars in thousands)
Computed tax at federal statutory rate$51,51521.0$33,35321.0$36,37521.0
Increases (reductions) resulting from:
State income taxes, net of federal income tax12,7565.29,7026.19,4295.4
Depletion allowance(2,756)(1.1)(2,123)(1.3)(1,893)(1.1)
Other9210.41,6691.0(452)(0.2)
Total income tax expense$62,43625.5$42,60126.8$43,45925.1

The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction, and various state and local jurisdictions. The Company is no longer subject to U.S. federal or non-U.S. income tax examinations by tax authorities for years ending prior to 2020. With few exceptions, as of December 31, 2023, the Company is no longer subject to state and local income tax examinations by tax authorities for years ending prior to 2020.

For the years ended December 31, 2023, 2022 and 2021, total reserves for uncertain tax positions were not material. The Company recognizes interest and penalties accrued relative to unrecognized tax benefits in income tax expense.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.